ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,741 to 4,760 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Composite of the Following: Acute/Urgent Care and/or Emergency Room Visits, Hospital Readmissions86 of 603

113 of 702

-1.8 points

-5.7 to 2.1

1,305NCT04057820

Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach

Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Inpatient Composite Safety Outcome Which Includes Seizures, Accidental Trauma, Respiratory Insufficiency Due to Opioid Therapy (Present/Absent)2 of 603

1 of 702

0.2 points

-0.5 to 1.1

1,305NCT04057820

Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach

Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: deaths from any cause0 of 603

4 of 702

-0.6 points

-1.5 to 0.2

1,305NCT04057820

Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach

Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Did Infant Receive Opioid Replacement Therapy (Yes/no)145 of 603

328 of 702

-22.7 points

-27.6 to -17.6

1,305NCT04057820

Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach

Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: serious adverse events12 of 603

4 of 702

1.4 points

0.2 to 2.9

1,305NCT04057820

Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach

Participants 10 to <11 Years of Age vs Participants 11 to <12 Years of Age: serious adverse events0 of 651

1 of 651

-0.2 points

-0.9 to 0.4

1,302NCT01311557

Study of Adacel® Vaccine Administered to Persons 10 Years of Age

Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel: deaths from any cause231 of 652

305 of 650

-11.5 points

-16.7 to -6.2

1,302NCT02799602

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel: serious adverse events306 of 652

276 of 650

4.5 points

-0.9 to 9.8

1,302NCT02799602

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

FDA Approved Regimen vs MK-3475 (Pembrolizumab): deaths from any cause130 of 654

131 of 647

-0.4 points

-4.7 to 4.0

1,301NCT02506153

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab vs Placebo With Paclitaxel, Carboplatin and Bevacizumab: deaths from any cause272 of 651

289 of 650

-2.7 points

-8.0 to 2.7

1,301NCT03038100

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Cardiovascular Collapse113 of 645

127 of 656

-1.8 points

-6.1 to 2.4

1,301NCT05267652

Pragmatic Trial Examining Oxygenation Prior to Intubation

Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Successful Intubation on the First Attempt534 of 645

535 of 656

1.2 points

-2.9 to 5.4

1,301NCT05267652

Pragmatic Trial Examining Oxygenation Prior to Intubation

Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: 28-day In-hospital Mortality209 of 645

217 of 656

-0.7 points

-5.8 to 4.4

1,301NCT05267652

Pragmatic Trial Examining Oxygenation Prior to Intubation

Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: deaths from any cause209 of 645

217 of 656

-0.7 points

-5.8 to 4.4

1,301NCT05267652

Pragmatic Trial Examining Oxygenation Prior to Intubation

Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Operator-reported Aspiration6 of 645

9 of 656

-0.4 points

-1.8 to 0.8

1,301NCT05267652

Pragmatic Trial Examining Oxygenation Prior to Intubation

Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: serious adverse events2 of 645

0 of 656

0.3 points

-0.3 to 1.1

1,301NCT05267652

Pragmatic Trial Examining Oxygenation Prior to Intubation

TA-7284-Low vs TA-7284-High: serious adverse events30 of 584

32 of 715

0.7 points

-1.7 to 3.1

1,299NCT01387737

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

MET and LIFE vs Healthy Lifestyle Intervention (LIFE): serious adverse events12 of 579

25 of 720

-1.4 points

-3.2 to 0.5

1,299NCT02515773

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

Cohort 1: Participants Aged 9 to 17 Years vs Cohort 2: Participants Aged 18 to 49 Years: Number of Participants With Immediate Unsolicited Adverse Events (AEs)1 of 641

0 of 658

0.2 points

-0.4 to 0.9

1,299NCT05513053

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Cohort 1: Participants Aged 9 to 17 Years vs Cohort 2: Participants Aged 18 to 49 Years: Number of Participants With Unsolicited AEs93 of 641

119 of 658

-3.6 points

-7.6 to 0.4

1,299NCT05513053

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=238"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=238

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04057820-52246e26",
        "title": "Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Composite of the Following: Acute/Urgent Care and/or Emergency Room Visits, Hospital Readmissions",
        "summary": "86 of 603 against 113 of 702; risk difference -1.8 points, 95% interval -5.7 to 2.1; NCT04057820, Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach",
        "record": "/library/comparisons/NCT04057820-52246e26",
        "nct_id": "NCT04057820",
        "kind": "outcome",
        "participants": 1305,
        "risk_difference": {
          "value": -0.018348428796190003,
          "lower": -0.05707986057198294,
          "upper": 0.021049040310868655
        },
        "group_1": "86 of 603",
        "group_2": "113 of 702",
        "difference": "-1.8 points",
        "interval": "-5.7 to 2.1",
        "trial_title": "Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach"
      },
      {
        "id": "NCT04057820-c8792884",
        "title": "Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Inpatient Composite Safety Outcome Which Includes Seizures, Accidental Trauma, Respiratory Insufficiency Due to Opioid Therapy (Present/Absent)",
        "summary": "2 of 603 against 1 of 702; risk difference 0.2 points, 95% interval -0.5 to 1.1; NCT04057820, Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach",
        "record": "/library/comparisons/NCT04057820-c8792884",
        "nct_id": "NCT04057820",
        "kind": "outcome",
        "participants": 1305,
        "risk_difference": {
          "value": 0.0018922481609048773,
          "lower": -0.005132748043640298,
          "upper": 0.010665978153554937
        },
        "group_1": "2 of 603",
        "group_2": "1 of 702",
        "difference": "0.2 points",
        "interval": "-0.5 to 1.1",
        "trial_title": "Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=239",
  "request_id": "XHypzLzWzwi3ZwOI"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?